El Ministerio de Ciencia e Innovación a través del de la Agencia Estatal de Investigación (AEI) ha concedido al VHIO…
Published ahead of print in Nature Medicine*, the final efficacy and safety results of the ROAR basket study led by…
Published in the journal Genes & Development*, results of a study led by Laura Soucek, co-Director of the Vall d’Hebron…
The RADPrecise project young investigators team, coordinated by Ester Aguado Flor from the VHIO Hereditary Cancer Genetics Group, has won…
CAR T-cell therapy consists of targeted immune system cell modification to attack the cells that produce the antibodies causing the…
Non-canonical proteins are unconventional protein products that are not part of the known protein-coding genome repertoire. They arise from unexpected…
Recently published in the Journal of Medical Genetics* results of a case-control study spearheaded by VHIO’s Judith Balmaña show that…
Futibatinib, an advanced FGFR inhibitor, has demonstrated effectiveness in impeding tumor growth among patients with FGFR-altered tumors. What is Intrahepatic…
Now published by the ESMO Daily Reporter (formerly by the ESMO Perspectives online magazine), the latest edition of On Target – Gathering…
Results of the phase II single arm, multi-site international CALYPSO study point to the efficacy of combining potent MET inhibitor…
A study led by researchers at the Hospital del Mar Medical Research Institute shows that the oxaliplatin administered in some…
Results of VHIO-led pharmacokinetic analysis of Omomyc, a therapeutic mini-protein that targets the MYC oncogene which is found deregulated in…
